In last trading session, Verrica Pharmaceuticals Inc (NASDAQ:VRCA) saw 0.5 million shares changing hands with its beta currently measuring 1.88. Company’s recent per share price level of $0.66 trading at $0.02 or 3.19% at ring of the bell on the day assigns it a market valuation of $61.26M. That closing price of VRCA’s stock is at a discount of -1365.15% from its 52-week high price of $9.67 and is indicating a premium of 42.42% from its 52-week low price of $0.38. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.29 million shares which gives us an average trading volume of 409.64K if we extend that period to 3-months.
For Verrica Pharmaceuticals Inc (VRCA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.33. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.08 in the current quarter.
Verrica Pharmaceuticals Inc (NASDAQ:VRCA) trade information
Upright in the green during last session for gaining 3.19%, in the last five days VRCA remained trading in the green while hitting it’s week-highest on Friday, 05/16/25 when the stock touched $0.66 price level, adding 8.33% to its value on the day. Verrica Pharmaceuticals Inc’s shares saw a change of -5.39% in year-to-date performance and have moved 50.52% in past 5-day. Verrica Pharmaceuticals Inc (NASDAQ:VRCA) showed a performance of 38.21% in past 30-days. Number of shares sold short was 2.71 million shares which calculate 6.82 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 12 to the stock, which implies a rise of 94.5% to its current value. Analysts have been projecting 10 as a low price target for the stock while placing it at a high target of 14. It follows that stock’s current price would drop -1415.15% in reaching the projected high whereas dropping to the targeted low would mean a loss of -1415.15% for stock’s current value.
Verrica Pharmaceuticals Inc (VRCA) estimates and forecasts
This year revenue growth is estimated to rise 157.28% from the last financial year’s standing.
5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 4.33M for the same. And 5 analysts are in estimates of company making revenue of 5.51M in the next quarter. Company posted 5.18M and -1.78M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -5.46% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 78.60% while estimates for its earnings growth in next 5 years are of 47.84%.
Verrica Pharmaceuticals Inc (NASDAQ:VRCA)’s Major holders
Insiders are in possession of 44.37% of company’s total shares while institution are holding 31.89 percent of that, with stock having share float percentage of 57.32%. Investors also watch the number of corporate investors in a company very closely, which is 31.89% institutions for Verrica Pharmaceuticals Inc that are currently holding shares of the company. PERCEPTIVE ADVISORS LLC is the top institutional holder at VRCA for having 7.1 million shares of worth $51.75 million. And as of 2024-06-30, it was holding 15.2663 of the company’s outstanding shares.
The second largest institutional holder is AVORO CAPITAL ADVISORS LLC, which was holding about 4.0 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.6017 of outstanding shares, having a total worth of $29.16 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.3 shares of worth $0.86 million or 1.40% of the total outstanding shares. The later fund manager was in possession of 551.49 shares on Mar 31, 2025 , making its stake of worth around $0.37 million in the company or a holder of 0.60% of company’s stock.
